Clinical trials: Mediastinal Grey Zone Lymphoma
Mediastinal Grey Zone Lymphoma
Mediastinal Grey Zone Lymphoma From the LYSA
Mediastinal grey zone lymphoma, B cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B cell lymphoma, are not well described in the literature.
- Trial name
- NCT03037177
- Where
- France
- Volunteers
- 99 people
- Sponsor
- Hospices Civils de Lyon
Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma
Amping up With PemJAK
The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
- Conditions
- Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Hodgkin Disease Recurrent
- Trial name
- NCT07283822
- Testing
- Ruxolitinib, Pembrolizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Seda S. Tolu
Non-Hodgkin Lymphoma
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
The purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) including Burkitt Lymphoma and…
- Trial name
- BIANCA (NCT03610724)
- Testing
- Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
- Where
- 26 sites in United States, Australia and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase II trial studies how well brentuximab vedotin, bendamustine, and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous…
- Conditions
- Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, Grey Zone Lymphoma, High Grade B Cell Lymphoma
- Trial name
- S-BR (NCT02623920)
- Testing
- Brentuximab, Bendamustine, Rituximab
- Where
- United States
- Sponsor
- University of Arizona
Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial tests the safety, side effects, and best dose of TTI-621 (closed to enrollment) or TTI-622 in combination with pembrolizumab in treating patients with diffuse large B-cell lymphoma that has come back after a…
- Conditions
- Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT05507541
- Testing
- Biospecimen Collection, Computed Tomography, Ontorpacept
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy with or without glofitamab for the treatment of patients with untreated large B-cell lymphoma that grows and spreads…
- Conditions
- Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT04231877
- Testing
- Polatuzumab Vedotin, Rituximab, Prednisone
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Washington
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back (recurrent) or do not respond to treatment (refractory).
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Trial name
- NCT03038672
- Testing
- Nivolumab, Varlilumab
- Where
- 33 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Lymphoma, NK/T Cell Lymphoma
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
This is a single-center, open label, single dose study of anti CD30 CAR-T cells injection in treatment of patients with relapsed/refractory CD30+ lymphoma.
- Conditions
- Hodgkin Lymphoma, NK/T Cell Lymphoma, Peripheral T Cell Lymphoma, Unspecified, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT05208853
- Testing
- Anti CD30 CAR-T Cell Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Zhejiang University
Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement (relapsed).
- Conditions
- Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT02568553
- Testing
- Blinatumomab, Lenalidomide
- Where
- 24 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive Diffuse Large B-Cell Lymphoma
Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
This is a Phase I/II multicenter single arm non-randomized open label study of the investigational drug, brentuximab vedotin, given in combination with routine chemotherapy (rituximab, cyclophosphamide, doxorubicin and…
- Conditions
- CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30-Positive Gray Zone Lymphoma
- Trial name
- NCT01994850
- Testing
- brentuximab vedotin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
5-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation. Etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin)(EPOCH): Etoposide…
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma, Anaplastic Large-Cell Lymphoma
- Trial name
- NCT00001337
- Testing
- Etoposide, Rituximab, Prednisone
- Where
- 5 sites in United States
- Volunteers
- 348 people
- Sponsor
- National Cancer Institute (NCI)